2021 Pediatric Grand Rounds | The Evolution of Pediatric Acute Lymphoblastic Leukemia (ALL) Trials
New trials often start before the full data analysis from the prior trials matures, leading to a more current trial that is utilizing old data. Analyzing the questions posed and status of the findings from prior trials will allow providers to understand the points of flexibility in current practice, current advances in the field, and titrate therapy accordingly.
Children’s Oncology Group is a large consortia encompassing the United States, Canada, Australia and New Zealand. Given that pediatric cancers are relatively rare, the wide catchment area allows advances in patient care to progress, both in novel therapeutics and novel diagnostics. The purpose of this presentation is to review the findings of the trials from the past 20 years including questions raised, results to date, quality of data, and current trends. Review of this information will allow a practicing pediatric oncologist to be able to modify therapy as needed for patients on a protocol more effectively as they will understand what is unknown in the current state, integrate current recommendations into clinical practice including routine germline testing, and rationally incorporate novel diagnostic evaluations such as next generation sequencing.
Pediatric Leukemia Providers including physicians, physician-assistants, and nurses.
- Demonstrate ability to tailor therapy to patient needs in a scientifically-sound manner.
- Integrate prior trial results into future trial design.
- Discuss outcomes from prior trials that have led to the current trial designs, where we have made progress and where we have plateaued in pediatric leukemia.
- Integrate tools that are advancing leukemia management, including next generation sequencing and germline sequencing.
Virtual Meeting- Zoom
Shilpa Shahani, MD Assistant Professor of Pediatrics, City of Hope
Dr. Shahani has indicated that she does not have anything to disclose.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2021 Pediatric Grand Rounds | The Evolution of Pediatric Acute Lymphoblastic Leukemia (ALL) Trials for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance